Synthetic Ex Vivo 3D Immune Organoids for B-Cell Culture & Production
- Detailed Technology Description
- This invention describes a synthetically engineered immune organoid for growth, proliferation, activation,differentiation, and immunoglobulin switching of primary naïve B cells in a threedimensional structure.
- Others
-
- Alberto Purwada & al. (2015). Ex vivoengineered immune organoids for controlled germinal center reactions. Biomaterials, Vol. 63:24–3 DOI:10.1016/j.biomaterials.2015.06.002.
- “Groupuses organoid to explain immune cells’ rapid response” By Tom Fleischman CornellChronicle October 12, 2017.
- *Abstract
-
Cornell researchers havecreated a functional, synthetic immune organ (B cell follicle organoid) made ofnanocomposite biomaterials, which recapitulates the anatomical microenvironmentof a lymphoid tissue. It is comprised inpart, of a RGD-presenting hydrogel system, reinforced with syntheticnanoparticles, the stiffness of which mimics the native secondary lymphoidtissue.
Compared to 2Dco-cultures, this novel 3D immune organoid resulted in 100-fold higher and morerapid differentiation of naïve primary B cells to the GC phenotype with robustantibody class switching (Fig.1shows an increase in the number of CD19+IgE+B cells over 6 days in 3D immuneorganoids or 2D co-cultures ).
Figure 1. IgEantibody expression in the immune organoid. Histogram representing the overlayof IgE expression for 2D and 3D co-cultures.
PotentialApplications
- Highaffinity monoclonal antibody production against specific antigens ex vivo
- Screeningof biotherapeutic compounds which target B-cells (eg. B-cell lymphoma)
- Implantimmune organoid to elicit an in vivoresponse (eg. against melanomas)
- Researchtool for real-time study of germinal center B cell physiology and pathology
Advantages
- Developmentand differentiation of primary naïve B cells into germinal centers (GC)phenotype
- AcceleratedGC reaction ex vivo
- Precisecontrol of the magnitude and rate of GC reaction
- Robustantibody class switching
- Thesystem does not require in vivoimplantation.
- *Licensing
- Phillip Owhpo62@cornell.edu1-607-254-4508
- Country/Region
- USA
